United Therapeutics (UTHR): Distributor relationships concentrate revenue and operational leverage

United Therapeutics is a commercial-stage biotechnology company that develops, manufactures and sells specialty therapies for pulmonary and other life‑threatening vascular diseases, monetizing primarily through direct product sales to specialty pharmaceutical distributors and through select international licensing partners. The company recognizes revenue at shipment to distributors and generates the vast majority of its top line from treprostinil‑based therapies (Tyvaso DPI, nebulized Tyvaso, Remodulin and Orenitram)—a structural fact that concentrates both revenue and operational dependence on a small set of downstream partners. For investors evaluating customer risk and commercial durability, the distribution network and contract posture are primary drivers of downside and upside. Learn more at https://nullexposure.com/.

How the commercial model shapes risk and value

United Therapeutics operates as a seller to a small number of specialty distributors in North America and through exclusive or territorial partners internationally. Key operating characteristics that investors must internalize:

• Concentration: The company reports that substantially all treprostinil‑based revenues in the U.S. are derived from two distributors, creating a single‑point concentration on the buyer side of the revenue ledger (see below).
• Contracting posture: The company has non‑exclusive framework distribution agreements with Accredo and CVS Specialty for most treprostinil products, and an exclusive distributor arrangement for Unituxin with Cencora/ASD Specialty Healthcare. This mix of non‑exclusive and exclusive contracts influences negotiation leverage and the speed of switching.
• Materiality and criticality: Treprostinil products comprised 56% of total revenue in 2024 ($1,620.4 million of combined Tyvaso DPI and nebulized Tyvaso sales), making distributor performance and purchasing cadence functionally critical to United Therapeutics’ income statement. (United Therapeutics 2024 Form 10‑K.)
• Geography: The commercial footprint is concentrated in North America for core products, with selected partners managing separate international commercialization and regulatory responsibilities.

These are company‑level signals investors should treat as persistent features of the business rather than transient noise.

Customer relationships: a line‑by‑line read for investors

Below I catalogue every customer or distribution relationship mentioned in the source material and summarize the commercial role in plain English with source context.

Accredo Health Group (10‑K entry)

Accredo was named in litigation referenced in the 2024 Form 10‑K and is one of the specialty pharmacies/distributors identified in the filing. According to the 2024 Form 10‑K, Accredo is a contracted specialty distributor for United Therapeutics’ treprostinil products. (United Therapeutics 2024 Form 10‑K, FY2024.)

CuraScript SD Specialty Distribution / Priority Healthcare Distribution, Inc. (10‑K)

The 10‑K cites Priority Healthcare Distribution doing business as CuraScript SD Specialty Distribution in contractual language; CuraScript appears as a wholesale purchaser/distributor under an agreement incorporated by reference in the filing. (United Therapeutics 2024 Form 10‑K, FY2024.)

CVS Health Corporation (10‑K entry)

CVS Health Corporation is named alongside Accredo and Express Scripts in litigation referenced in the 2024 Form 10‑K and is identified as a commercial channel participant connected to specialty pharmacy distribution. (United Therapeutics 2024 Form 10‑K, FY2024.)

Express Scripts Holding Company (10‑K entry)

Express Scripts Holding Company is likewise named in the 10‑K’s litigation disclosure as one of the specialty pharmacy entities noted in the company’s legal discussion. (United Therapeutics 2024 Form 10‑K, FY2024.)

Express Scripts, Inc. (10‑K entry)

Express Scripts, Inc. is separately named in the filing’s litigation context and appears as a specialty pharmacy/distribution channel referenced in the same section. (United Therapeutics 2024 Form 10‑K, FY2024.)

CVS (news/SEC filing summary)

A news summary of the 10‑K highlights that United Therapeutics derives substantially all U.S. treprostinil‑based revenues from two distributors: Accredo and CVS Specialty, and confirms separate non‑exclusive distribution agreements with both. (StockTitan summary of United Therapeutics 10‑K, Mar 2026.)

CVS Specialty (news/SEC filing summary)

CVS Specialty (Caremark, L.L.C.) is one of the two contracted U.S. specialty distributors for Tyvaso products and Remodulin; the company lists non‑exclusive distribution agreements with CVS Specialty in its annual filing commentary. (StockTitan summary of United Therapeutics 10‑K, Mar 2026.)

Accredo (news/SEC filing summary)

The news‑summarized 10‑K reiterates Accredo as the other contracted U.S. specialty distributor and names Accredo repeatedly as the counterparty for treprostinil sales. (StockTitan summary of United Therapeutics 10‑K, Mar 2026.)

Cencora Global Procurement Ltd. (news/SEC filing summary)

United Therapeutics states an exclusive distribution agreement with Cencora Global Procurement Ltd. to distribute Unituxin in the United States, differentiating Unituxin’s channel from the treprostinil products. (StockTitan summary of United Therapeutics 10‑K, Mar 2026.)

Accredo Health Group, Inc. (Accredo) — alternate mention (news)

The filing language specifies Accredo Health Group, Inc. and its affiliates as a contracted specialty distributor for U.S. treprostinil product distribution. (StockTitan summary of United Therapeutics 10‑K, Mar 2026.)

Caremark, L.L.C. (CVS Specialty) — alternate mention (news)

Caremark, L.L.C. is the legal entity referenced for CVS Specialty’s role as a contracted U.S. distributor for the company’s core products. (StockTitan summary of United Therapeutics 10‑K, Mar 2026.)

Cencora Global Procurement Ltd (Cencora) — alternate mention

The 10‑K summary reiterates the exclusive Unituxin distribution relationship with Cencora, confirming that Unituxin follows a different distribution model from treprostinil lines. (StockTitan summary of United Therapeutics 10‑K, Mar 2026.)

Grupo Ferrer Internacional, S.A. (Ferrer)

Ferrer is identified as United Therapeutics’ primary distributor outside the United States for Remodulin, holding marketing authorization rights in many non‑U.S. territories. (StockTitan summary of United Therapeutics 10‑K, Mar 2026.)

Ohara Pharmaceutical Co., Ltd.

Ohara is the exclusive distributor for Unituxin in Japan and obtained Japanese marketing authorization for the product during the second quarter of 2021, according to the filing summary. (StockTitan summary of United Therapeutics 10‑K, Mar 2026.)

Accredo Health Group, Inc. — Specialty Pharmacy Network Agreement (news)

United Therapeutics’ filings incorporate by reference a Specialty Pharmacy Network Agreement dated January 1, 2018 with Accredo Health Group, Inc., evidencing formalized contractual terms between the parties. (StockTitan summary of United Therapeutics 10‑K, Mar 2026; 10‑K exhibits referenced.)

Priority Healthcare Distribution, Inc. (d/b/a CuraScript SD Specialty Distribution) — Wholesale Purchase Agreement (news)

The company references a Wholesale Product Purchase Agreement dated January 1, 2018 with Priority Healthcare Distribution, Inc. (d/b/a CuraScript SD), showing a standing purchase relationship for U.S. distribution channels. (StockTitan summary of United Therapeutics 10‑K, Mar 2026; 10‑K exhibits referenced.)

Mochida Pharmaceutical Co., Ltd. (Mochida)

United Therapeutics sells Nebulized Tyvaso exclusively through Mochida in Japan, where approvals expanded to include PAH (late 2022) and PH‑ILD (2024). (StockTitan summary of United Therapeutics 10‑K, Mar 2026.)

LLY / Lilly (10‑K entries)

United Therapeutics holds an exclusive 2008 license from Eli Lilly to develop, market and commercialize Adcirca for pulmonary hypertension in the United States—an IP/licensing relationship noted in the 2024 Form 10‑K. (United Therapeutics 2024 Form 10‑K, FY2024.)

What the contract excerpts and constraints tell investors

The company’s own disclosures and the excerpts summarized above create a clear investment checklist:

• Revenue concentration in trim lines: Treprostinil-based therapies accounted for 56% of 2024 revenue; this is a material and critical revenue stream. (United Therapeutics 2024 Form 10‑K.)
• Distribution concentration in North America: Substantial U.S. treprostinil sales flow through two distributors—Accredo and CVS Specialty—creating counterparty concentration and negotiating leverage issues.
• Contract types: United Therapeutics uses non‑exclusive framework distribution agreements with Accredo and CVS Specialty for treprostinil products, while Unituxin follows an exclusive U.S. distribution path with Cencora/ASD. This combination determines revenue stickiness and switching risk.
• Active commercial stage: Product launches (e.g., Tyvaso DPI) and ongoing shipments are in commercial operation, so partner behavior has immediate P&L impact.

Investment implications and next steps

United Therapeutics offers a high‑quality product portfolio with attractive margins, but investors must underwrite distributor concentration and the impact of contract renewals or commercial disputes on near‑term cash flow. Monitor: (1) purchasing cadence from Accredo and CVS Specialty, (2) any renegotiation of framework agreements, (3) Cencora’s performance on Unituxin, and (4) international partner rollouts (Ferrer, Mochida, Ohara). For a research‑grade dive into contractual exposures and counterparty lists, visit https://nullexposure.com/ for our structured coverage and flagged risk items.

Bold takeaway: United Therapeutics is commercially strong but operationally dependent—two U.S. distributors and a handful of international partners concentrate delivery risk that investors must model explicitly.